Version 2 2020-11-23, 16:44Version 2 2020-11-23, 16:44
Version 1 2020-07-01, 09:52Version 1 2020-07-01, 09:52
journal contribution
posted on 2020-11-23, 16:44authored byMuhammad Israr, Andrea Salzano, Yoshiyuki Yazaki, Adriaan A Voors, Wouter Ouwerkerk, Stefan D Anker, John G Cleland, Kenneth Dickstein, Marco Metra, Nilesh J Samani, Leong L Ng, Toru Suzuki
Natriuretic peptides [NP, including B-type
natriuretic peptide (BNP) and amino-terminal
prohormone of BNP (NT-proBNP)] are
the gold-standard biomarkers in heart failure (HF) management,1 with NP levels at
presentation/admission routinely used for
diagnostic and prognostic purposes. NP
levels at discharge/follow-up also show
association with outcomes, and NP levels
following HF treatment add further value to
tailoring risk. However, the usefulness of NP
serial measurements beyond conventional
HF treatment in clinical practice still remains
a matter of controversy. A cohort with
current HF guideline-based treatment would
provide an ideal setting to revisit usefulness
of NP serial measurements in risk stratification of HF patients, including the role of
recently identified BNP molecular forms.
The European multi-national BIOlogy Study
to TAilored Treatment in Chronic Heart
Failure (BIOSTAT-CHF) provides an opportunity for the aforementioned analysis, being
a European cohort in which serial sampling of
NPs was done before and after titration of HF
medications according to current European
guidelines in a multi-centre, observational,
real-world setting.
History
Citation
European Journal of Heart Failure, Volume 22, Issue 8, August 2020, Pages 1486-1490